Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 185

Sort by

Sort Order Select

Journal Articles

A factor VIIIa–mimetic bispecific antibody, Mim8, ameliorates bleeding upon severe vascular challenge in hemophilia A mice

Blood (2021) 138 (14): 1258–1268.

https://doi.org/10.1182/blood.2020010331

Published: 2021

Includes: Supplemental data

Journal Articles

Efficacy of OR21, a Novel Oral Demethylating Agent in Chronic Myeloid Leukemia

Kazuharu Kamachi, MD, Hiroshi Ureshino, MD, Nao Yoshida, MD, Yuki Kurahashi, Tatsuro Watanabe, PhD, Seiji Okada, MD PhD, Shinya Kimura, MD PhD

Blood (2019) 134 (Supplement_1): 5365.

https://doi.org/10.1182/blood-2019-125460

Published: 2019

Journal Articles

CTX-8573, an Innate-Cell Engager Targeting BCMA, is a Highly Potent Multispecific Antibody for the Treatment of Multiple Myeloma

Blood (2019) 134 (Supplement_1): 3182.

https://doi.org/10.1182/blood-2019-128749

Published: 2019

Journal Articles

TNB-486, a Novel Fully Human Bispecific CD19 x CD3 Antibody That Kills CD19-Positive Tumor Cells with Minimal Cytokine Secretion

Harbani Malik, PhD, Ben Buelow, MD PhD, Udaya Rangaswamy, PhD, Aarti Balasubramani, Andrew Boudreau, Kevin Dang, Laura Davison, PhD, Shelley Force Aldred, Katherine Marie Harris, MD, Suhasini Iyer, PhD, Brett Jorgensen, PhD, Duy Pham, MBA, Kirthana Prabhakar, Ute Schellenberger, PhD, Harshad Ugamraj, Nathan Trinklein, PhD, Wim Van Schooten, PhD

Blood (2019) 134 (Supplement_1): 4070.

https://doi.org/10.1182/blood-2019-123226

Published: 2019

Journal Articles

TJC4, a Differentiated Anti-CD47 Antibody with Novel Epitope and RBC Sparing Properties

Zhen Meng, PhD, Zhengyi Wang, PhD, Bingshi Guo, PhD, Wei Cao, PhD, Huaqiong Shen, MD PhD

Blood (2019) 134 (Supplement_1): 4063.

https://doi.org/10.1182/blood-2019-122793

Published: 2019

Journal Articles

Mim8 - a Next-Generation FVIII Mimetic Bi-Specific Antibody - Potently Restores the Hemostatic Capacity in Hemophilia a Settings in Vitro and In Vivo

Blood (2019) 134 (Supplement_1): 96.

https://doi.org/10.1182/blood-2019-122817

Published: 2019

Journal Articles

First-in-Human, Phase 1/2 Trial to Assess the Safety and Clinical Activity of Subcutaneous GEN3013 (DuoBody ® -CD3×CD20) in B-Cell Non-Hodgkin Lymphomas

Pieternella Lugtenburg, MD PhD, Rogier Mous, MD PhD, Michael Roost Clausen, Martine E.D. Chamuleau, Peter Johnson, MDFRCP, Kim Linton, PhD, Simon Rule, Roberto S Oliveri, MD PhD, Dena DeMarco, Ida H Hiemstra, PhD, Guang Chen, Ada Azaryan, Manish Gupta, Tahamtan Ahmadi, Martin Hutchings, MD PhD

Blood (2019) 134 (Supplement_1): 758.

https://doi.org/10.1182/blood-2019-121460

Published: 2019

Journal Articles

High Avidity IgM-Based CD20xCD3 Bispecific Antibody (IGM-2323) for Enhanced T-Cell Dependent Killing with Minimal Cytokine Release

Ramesh Baliga, PhD, Keyu Li, PhD, Marigold Manlusoc, Paul Hinton, Dean Ng, PhD, Madeline Tran, Bing Shan, PhD, Hai Lu, Avneesh Saini, PhD, Sachi Rahman, Yuan Cao, PhD, Chitra Saraiya, Marvin Peterson, PhD, Steve Carroll, PhD, Daniel Chen, MD PhD, Bruce Keyt, PhD

Blood (2019) 134 (Supplement_1): 1574.

https://doi.org/10.1182/blood-2019-131650

Published: 2019

Journal Articles

MAA868, a novel FXI antibody with a unique binding mode, shows durable effects on markers of anticoagulation in humans

Blood (2019) 133 (13): 1507–1516.

https://doi.org/10.1182/blood-2018-10-880849

Published: 2019

Includes: Supplemental data

Journal Articles

Targeting CD45 with an Amanitin Antibody-Drug Conjugate Effectively Depletes Human HSCs and Immune Cells for Transplant Conditioning

Blood (2018) 132 (Supplement 1): 4526.

https://doi.org/10.1182/blood-2018-99-117167

Published: 2018

Journal Articles

Therapeutic Potential of AO-176, a Next Generation Humanized CD47 Antibody, for Hematologic Malignancies

W. Casey Wilson, PhD, Myriam N Bouchlaka, BS, PhD, Ben J Capoccia, PhD, Ronald R Hiebsch, BS, Michael J Donio, BS, Robyn J Puro, PhD, Alun J Carter, PhD, Prabir Chakraborty, PhD, Pamela T Manning, PhD, Robert W Karr, MD, Vicki Sung, PhD, Daniel S Pereira, PhD

Blood (2018) 132 (Supplement 1): 4180.

https://doi.org/10.1182/blood-2018-99-118456

Published: 2018

Journal Articles

A Next-Generation Fc-Bearing CD3-Engaging Bispecific DART ® Platform with Extended Pharmacokinetic and Expanded Pharmacologic Window: Characterization As CD123 x CD3 and CD19 x CD3 DART Molecules

Ezio Bonvini, MD, Ross La Motte-Mohs, PhD, Ling Huang, Chia-Ying Kao Lam, PhD, Thomas Kaufman, Liqin Liu, PhD, Ralph F. Alderson, PhD, Kurt Stahl, Jennifer G. Brown, PhD, Hua Li, Sharad Sharma, PhD, James Tamura, PhD, Syd Johnson, PhD, Paul Moore, PhD

Blood (2018) 132 (Supplement 1): 5230.

https://doi.org/10.1182/blood-2018-99-116264

Published: 2018

Journal Articles

Development of a Pegylated Dimeric Recombinant Factor VIII-Fc Fusion Protein for the Treatment for Hemophilia a Patients

Bin Liu, PhD, Xiaoshan Wang, Master, Xueqin Li, Master, Haixia Yan, PhD, Shuya Wang, Master, Xi Zhu, Pengju Wang, Jie Gao, Master, Yali Wang, PhD, Hongsheng Su, PhD

Blood (2018) 132 (Supplement 1): 3783.

https://doi.org/10.1182/blood-2018-99-112030

Published: 2018

Journal Articles

Absence of Plasma Gastric Biomarker Elevations with Chronic Dosing of Avatrombopag, a Novel Oral Thrombopoietin Receptor Agonist, in Patients with Chronic Immune Thrombocytopenia in Phase 3 Trials

James B. Bussel, MD, Lee F. Allen, MD PhD, Wei Tian, PhD, David J. Kuter, MD DPhil

Blood (2018) 132 (Supplement 1): 3740.

https://doi.org/10.1182/blood-2018-99-116873

Published: 2018

Journal Articles

SKY59: A Long-Lasting Engineered Anti-C5 Antibody for Subcutaneously Injectable Anti-Complement Therapy

Kenta Haraya, PhD, Zenjiro Sampei, PhD, Tatsuhiko Tachibana, PhD, Taku Fukuzawa, PhD, Siok Wan Gan, PhD, Meiri Shida-Kawazoe, PhD, Yuichiro Shimizu, PhD, Masaru Muraoka, PhD, Tomoyuki Igawa, PhD, Takehisa Kitazawa, DVM, Junichi Nezu, PhD

Blood (2018) 132 (Supplement 1): 3611.

https://doi.org/10.1182/blood-2018-99-110145

Published: 2018

Journal Articles

CD117-Amanitin Antibody Drug Conjugates Effectively Deplete Human and Non-Human Primate HSCs: Proof of Concept As a Targeted Strategy for Conditioning Patients for Bone Marrow Transplant

Bradley R Pearse, PhD, Sean M McDonough, MS, Jennifer L Proctor, BS, Rajiv Panwar, PhD, Ganapathy Sarma, PhD, Molly A McShea, MS, Lena Kien, BS, Junia Dushime, BS, Hillary L Adams, MS, Sharon L. Hyzy, MS, Melissa L. Brooks, BS, Rahul Palchaudhuri, PhD, Qing Li, PhD, Nathan M Kallen, BA, Pranoti Sawant, MS, Charlotte F McDonagh, PhD, Anthony E. Boitano, PhD, Michael P. Cooke, PhD

Blood (2018) 132 (Supplement 1): 3314.

https://doi.org/10.1182/blood-2018-99-114881

Published: 2018

Journal Articles

A Novel Full Length Anti-FLT3 CD3 Bispecific Antibody for the Treatment of Acute Myeloid Leukemia

Ivana Djuretic, PhD, Veena Krishnamoorthy, PhD, Cesar Sommer, PhD, Danielle E. Dettling, Kris Poulsen, Wei Chen, PhD, Wenyue Hu, PhD, Allison Given Chunyk, Kevin Lindquist, Shobha Potluri, PhD, Robert C Rickert, PhD, Barbra Sasu, PhD, Javier Chaparro-Riggers, PhD, Yik Andy Yeung, PhD

Blood (2018) 132 (Supplement 1): 1445.

https://doi.org/10.1182/blood-2018-99-119915

Published: 2018

Journal Articles

OR21, a New Oral DNA Methyltransferase Inhibitor for Treatment of MDS and AML

Hiroshi Ureshino, MD, Tatsuro Watanabe, PhD, Yuki Kurahashi, Yuki Fukuda Kurahashi, Kaoru Tohyama, MD, Seiji Okada, MD PhD, Toshikazu Ushijima, MD PhD, Hiroshi Ureshino, MD PhD

Blood (2018) 132 (Supplement 1): 5499.

https://doi.org/10.1182/blood-2018-99-112362

Published: 2018

Journal Articles

A Novel RAD51 Inhibitor, CYT01B, Shows Anti-Cancer Activity in Preclinical Models of Aid Expressing Lymphomas

Muneer G Hasham, PhD, Darryl Patrick, Leanne Bedard, Joseph Vacca, Casey McComas, Alfredo Castro, Melinda Day, PhD, Kevin Mills, PhD

Blood (2018) 132 (Supplement 1): 2944.

https://doi.org/10.1182/blood-2018-99-119351

Published: 2018

Journal Articles

Preclinical and Nonclinical Characterization of HPN217: A Tri-Specific T Cell Activating Construct (TriTAC) Targeting B Cell Maturation Antigen (BCMA) for the Treatment of Multiple Myeloma

Che-Leung Law, BSc,PhD, Wade Aaron, Rick Austin, Manasi Barath, Evan Callihan, Thomas Evans, Maria Gamez Guerrero, Golzar Hemmati, Adrie Jones, Kathryn Kwant, Llewelyn Lao, Bryan Lemon, Katrine Moldt, Purbasa Patnaik, Kenneth Sexton, Holger Wesche, Yinghua Xiao, Stephen Yu, Tim Yu

Blood (2018) 132 (Supplement 1): 3225.

https://doi.org/10.1182/blood-2018-99-113921

Published: 2018

NARROW

A factor VIIIa–mimetic bispecific antibody, Mim8, ameliorates bleeding upon severe vascular challenge in hemophilia A mice

Efficacy of OR21, a Novel Oral Demethylating Agent in Chronic Myeloid Leukemia

CTX-8573, an Innate-Cell Engager Targeting BCMA, is a Highly Potent Multispecific Antibody for the Treatment of Multiple Myeloma

TNB-486, a Novel Fully Human Bispecific CD19 x CD3 Antibody That Kills CD19-Positive Tumor Cells with Minimal Cytokine Secretion

TJC4, a Differentiated Anti-CD47 Antibody with Novel Epitope and RBC Sparing Properties

Mim8 - a Next-Generation FVIII Mimetic Bi-Specific Antibody - Potently Restores the Hemostatic Capacity in Hemophilia a Settings in Vitro and In Vivo

First-in-Human, Phase 1/2 Trial to Assess the Safety and Clinical Activity of Subcutaneous GEN3013 (DuoBody ® -CD3×CD20) in B-Cell Non-Hodgkin Lymphomas

High Avidity IgM-Based CD20xCD3 Bispecific Antibody (IGM-2323) for Enhanced T-Cell Dependent Killing with Minimal Cytokine Release

MAA868, a novel FXI antibody with a unique binding mode, shows durable effects on markers of anticoagulation in humans

Targeting CD45 with an Amanitin Antibody-Drug Conjugate Effectively Depletes Human HSCs and Immune Cells for Transplant Conditioning

Therapeutic Potential of AO-176, a Next Generation Humanized CD47 Antibody, for Hematologic Malignancies

A Next-Generation Fc-Bearing CD3-Engaging Bispecific DART ® Platform with Extended Pharmacokinetic and Expanded Pharmacologic Window: Characterization As CD123 x CD3 and CD19 x CD3 DART Molecules

Development of a Pegylated Dimeric Recombinant Factor VIII-Fc Fusion Protein for the Treatment for Hemophilia a Patients

Absence of Plasma Gastric Biomarker Elevations with Chronic Dosing of Avatrombopag, a Novel Oral Thrombopoietin Receptor Agonist, in Patients with Chronic Immune Thrombocytopenia in Phase 3 Trials

SKY59: A Long-Lasting Engineered Anti-C5 Antibody for Subcutaneously Injectable Anti-Complement Therapy

CD117-Amanitin Antibody Drug Conjugates Effectively Deplete Human and Non-Human Primate HSCs: Proof of Concept As a Targeted Strategy for Conditioning Patients for Bone Marrow Transplant

A Novel Full Length Anti-FLT3 CD3 Bispecific Antibody for the Treatment of Acute Myeloid Leukemia

OR21, a New Oral DNA Methyltransferase Inhibitor for Treatment of MDS and AML

A Novel RAD51 Inhibitor, CYT01B, Shows Anti-Cancer Activity in Preclinical Models of Aid Expressing Lymphomas

Preclinical and Nonclinical Characterization of HPN217: A Tri-Specific T Cell Activating Construct (TriTAC) Targeting B Cell Maturation Antigen (BCMA) for the Treatment of Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only